NBIX — Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Kyle W. Gano Ph.D., based in 12780 El Camino Real, San Diego, CA, United States, 92130, with about 1,800 employees. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Latest reported NBIX revenue for 2025-09-30 was $794.9M. Net income was $209.5M. Revenue was up 15.6% from 2025-06-30 to 2025-09-30. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.

Use this NBIX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NBIX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NBIX SEC filings page. Lician reads the product cache first so this HTML stays unique to Neurocrine Biosciences Inc even when a live quote feed is slow.